Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2025-12-26 @ 4:08 AM
Study NCT ID:
NCT06178718
Status:
COMPLETED
Last Update Posted:
2025-04-25
First Post:
2023-12-07
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D022124', 'term': 'Hyperammonemia'}], 'ancestors': [{'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000619733', 'term': 'TNP-2092'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'info@tennorx.com', 'phone': '0512-86861990', 'title': 'TenNor', 'organization': 'TenNor Therapeutics (Suzhou) Limited.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Up to 8 days after the first dosing.', 'eventGroups': [{'id': 'EG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 100mg on Day 1 in fasting state.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 200mg on Day 1 in fasting state.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 1, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'TNP-2092 Capsules 400mg (Fasting )', 'description': 'Participants received oral dose of TNP-2092 capsules 400mg in fasting state.', 'otherNumAtRisk': 16, 'deathsNumAtRisk': 16, 'otherNumAffected': 2, 'seriousNumAtRisk': 16, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 800mg on Day 1 in fasting state.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 1, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 1200mg on Day 1 in fasting state.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 1, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Placebo (Fasting)', 'description': 'Participants received TNP-2092 placebo capsules in fasting state.', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 1, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'TNP-2092 Capsules 400mg - (Fed)', 'description': 'Participants received oral dose of TNP-2092 capsules 400mg in fed state.', 'otherNumAtRisk': 16, 'deathsNumAtRisk': 16, 'otherNumAffected': 2, 'seriousNumAtRisk': 16, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Placebo (Fed)', 'description': 'Participants received placebo in fed state, with 1 participant in each of the 400 mg groups A and B.', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 0, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Activated partial thromboplastin time prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood glucose increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood bilirubin unconjugated increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Acarodermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 16, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 16, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '10', 'groupId': 'OG005'}, {'value': '16', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 100mg on Day 1 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 200mg on Day 1 in fasting state.'}, {'id': 'OG002', 'title': 'TNP-2092 Capsules 400mg (Fasting )', 'description': 'Participants received oral dose of TNP-2092 capsules 400mg in fasting state.'}, {'id': 'OG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 800mg on Day 1 in fasting state.'}, {'id': 'OG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 1200mg on Day 1 in fasting state.'}, {'id': 'OG005', 'title': 'Placebo (Fasting)', 'description': 'Participants received TNP-2092 placebo capsules in fasting state.'}, {'id': 'OG006', 'title': 'TNP-2092 Capsules 400mg - (Fed)', 'description': 'Participants received oral dose of TNP-2092 capsules 400mg in fed state.'}, {'id': 'OG007', 'title': 'Placebo (Fed)', 'description': 'Participants received placebo in fed state, with 1 participant in each of the 400 mg groups A and B.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 8 days after the first dosing.', 'description': 'To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have received at least one dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG002', 'title': 'TNP-2092 Capsules 400mg Group A (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}], 'classes': [{'categories': [{'measurements': [{'value': '67.9', 'spread': '29.9', 'groupId': 'OG000'}, {'value': '164', 'spread': '65.7', 'groupId': 'OG001'}, {'value': '201', 'spread': '71.4', 'groupId': 'OG002'}, {'value': '408', 'spread': '480', 'groupId': 'OG003'}, {'value': '339', 'spread': '176', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h*µg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG002', 'title': 'TNP-2092 Capsules 400mg Group A (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}], 'classes': [{'categories': [{'measurements': [{'value': '65.4', 'spread': '28.8', 'groupId': 'OG000'}, {'value': '161', 'spread': '65.0', 'groupId': 'OG001'}, {'value': '197', 'spread': '71.0', 'groupId': 'OG002'}, {'value': '404', 'spread': '478', 'groupId': 'OG003'}, {'value': '335', 'spread': '175', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h*µg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG002', 'title': 'TNP-2092 Capsules 400mg Group A (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state'}, {'id': 'OG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}], 'classes': [{'categories': [{'measurements': [{'value': '16.7', 'spread': '7.80', 'groupId': 'OG000'}, {'value': '41.7', 'spread': '17.9', 'groupId': 'OG001'}, {'value': '48.5', 'spread': '20.8', 'groupId': 'OG002'}, {'value': '97.4', 'spread': '117', 'groupId': 'OG003'}, {'value': '70.3', 'spread': '41.2', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'µg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG002', 'title': 'TNP-2092 Capsules 400mg Group A (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.76', 'spread': '0.46', 'groupId': 'OG000'}, {'value': '3.50', 'spread': '0.53', 'groupId': 'OG001'}, {'value': '3.50', 'spread': '1.20', 'groupId': 'OG002'}, {'value': '3.75', 'spread': '1.04', 'groupId': 'OG003'}, {'value': '3.25', 'spread': '1.17', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG002', 'title': 'TNP-2092 Capsules 400mg Group A (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 in fasting state.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.348', 'spread': '1.0494', 'groupId': 'OG000'}, {'value': '2.778', 'spread': '1.1949', 'groupId': 'OG001'}, {'value': '2.553', 'spread': '1.2619', 'groupId': 'OG002'}, {'value': '2.819', 'spread': '0.8444', 'groupId': 'OG003'}, {'value': '3.278', 'spread': '1.1161', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 400mg (Fasting)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 capsules 400 mg in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 400mg (Fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fed state.'}], 'classes': [{'categories': [{'measurements': [{'value': '214', 'spread': '91.7', 'groupId': 'OG000'}, {'value': '632', 'spread': '349', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h*µg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 400mg (Fasting)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 400mg (Fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fed state.'}], 'classes': [{'categories': [{'measurements': [{'value': '211', 'spread': '90.6', 'groupId': 'OG000'}, {'value': '628', 'spread': '349', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h*µg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 400mg (Fasting)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 400mg (Fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fed state.'}], 'classes': [{'categories': [{'measurements': [{'value': '50.2', 'spread': '25.2', 'groupId': 'OG000'}, {'value': '102', 'spread': '36.6', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'µg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 400mg (Fasting)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 400mg (Fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fed state.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.56', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '6.94', 'spread': '2.72', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}, {'type': 'PRIMARY', 'title': 'Terminal Elimination Half-life (T1/2) in Food Effect Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '16', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'TNP-2092 Capsules 400mg (Fasting)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fasting state.'}, {'id': 'OG001', 'title': 'TNP-2092 Capsules 400mg (Fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A and Group B received single oral dose of TNP-2092 in fed state.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.74', 'spread': '1.24', 'groupId': 'OG000'}, {'value': '3.69', 'spread': '0.98', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who have been randomized into groups, have received at least one dose of study drug, and have at least one evaluable pharmacokinetic parameter.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 100mg on Day 1 in fasting state.'}, {'id': 'FG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 200mg on Day 1 in fasting state.'}, {'id': 'FG002', 'title': 'TNP-2092 Capsules 400mg - Group A (Fasting - Fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A completed single ascending dose study and food effect study.\n\nParticipants received oral dose of TNP-2092 capsules 400mg on Day 1 in fasting state, and in fed state on Day 5 with a 4-day wash-out period.'}, {'id': 'FG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 800mg on Day 1 in fasting state.'}, {'id': 'FG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 1200mg on Day 1 in fasting state.'}, {'id': 'FG005', 'title': 'Placebo (Fasting)', 'description': 'Participants received TNP-2092 placebo capsules on Day 1 in fasting state, including 2 participants each in 100, 200, 800 and 1200 mg dose group.'}, {'id': 'FG006', 'title': 'TNP-2092 Capsules 400mg - Group B (Fed -Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 400mg on Day 1 in fed state, and in fasting state on Day 5 with a 4-day wash-out period.'}, {'id': 'FG007', 'title': 'Placebo (Fed-fasting)', 'description': 'One participant in 400 mg group B received TNP-2092 placebo capsules on Day 1 in fed state, and in fasting state on Day 5 with a 4-day wash-out period.'}, {'id': 'FG008', 'title': 'Placebo (Fasting-fed)', 'description': 'One participant in 400 mg group A received TNP-2092 placebo capsules on Day 1 in fasting state, and in fed state on Day 5 with a 4-day wash-out period.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '8'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '1'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '8'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '1'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '8', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '58', 'groupId': 'BG008'}]}], 'groups': [{'id': 'BG000', 'title': 'TNP-2092 Capsules 100mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 100mg on Day 1 in fasting state.'}, {'id': 'BG001', 'title': 'TNP-2092 Capsules 200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 200mg on Day 1 in fasting state.'}, {'id': 'BG002', 'title': 'TNP-2092 Capsules 400mg - Group A (Fasting-fed)', 'description': 'Participants in TNP-2092 capsules 400mg Group A completed single ascending dose study and food effect study.\n\nParticipants received oral dose of TNP-2092 capsules 400mg on Day 1 in fasting state, and in fed state on Day 5 with a 4-day wash-out period.'}, {'id': 'BG003', 'title': 'TNP-2092 Capsules 800mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 800mg on Day 1 in fasting state.'}, {'id': 'BG004', 'title': 'TNP-2092 Capsules 1200mg (Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 1200mg on Day 1 in fasting state.'}, {'id': 'BG005', 'title': 'Placebo (Fasting)', 'description': 'Participants received TNP-2092 placebo capsules on Day 1 in fasting state, including 2 participants each in 100, 200, 800, 1200 mg dose group, and 1 participant in 400 mg group A.'}, {'id': 'BG006', 'title': 'TNP-2092 Capsules 400mg - Group B (Fed -Fasting)', 'description': 'Participants received single oral dose of TNP-2092 capsules 400mg on Day 1 in fed state, and in fasting state on Day 5 with a 4-day wash-out period.'}, {'id': 'BG007', 'title': 'Placebo (Fed-fasting)', 'description': 'Participants received placebo on Day 1 in fed state, and in fasting state on Day 5 with a 4-day wash-out period, including one participant in 400 mg group B.'}, {'id': 'BG008', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '8', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '58', 'groupId': 'BG008'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '29.5', 'spread': '9.07', 'groupId': 'BG000'}, {'value': '33.6', 'spread': '7.96', 'groupId': 'BG001'}, {'value': '29.3', 'spread': '5.34', 'groupId': 'BG002'}, {'value': '28.9', 'spread': '10.32', 'groupId': 'BG003'}, {'value': '25.3', 'spread': '5.85', 'groupId': 'BG004'}, {'value': '28.3', 'spread': '8.72', 'groupId': 'BG005'}, {'value': '24.9', 'spread': '5.96', 'groupId': 'BG006'}, {'value': '19', 'spread': '0', 'groupId': 'BG007'}, {'value': '29.1', 'spread': '8.04', 'groupId': 'BG008'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '24', 'groupId': 'BG008'}]}, {'title': 'Male', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '34', 'groupId': 'BG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}, {'title': 'Asian', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '8', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '58', 'groupId': 'BG008'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}, {'title': 'White', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-05-19', 'size': 297173, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-12-30T02:22', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 58}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-06-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2016-08-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-08', 'studyFirstSubmitDate': '2023-12-07', 'resultsFirstSubmitDate': '2024-09-14', 'studyFirstSubmitQcDate': '2023-12-20', 'lastUpdatePostDateStruct': {'date': '2025-04-25', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-04-08', 'studyFirstPostDateStruct': {'date': '2023-12-21', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-04-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-08-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)', 'timeFrame': 'Up to 8 days after the first dosing.', 'description': 'To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}, {'measure': 'Terminal Elimination Half-life (T1/2) in Food Effect Study', 'timeFrame': 'Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration', 'description': 'Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Hyperammonemia']}, 'descriptionModule': {'briefSummary': 'The aim of the study was to evaluate the tolerability and pharmacokinetic characteristics of TNP-2092 Capsules after single-dose administration in healthy subjects, and the food effect on pharmacokinetics.', 'detailedDescription': 'This was a single-center, randomized, double-blind, placebo-controlled, dose-ascending single-dose-administration study, and a study on the food effects on pharmacokinetics. Five dose groups of 100 mg, 200 mg, 400 mg, 800 mg, and 1200 mg will be set up.\n\nThe 100 mg, 200 mg, 800 mg, and 1200 mg groups will complete the single ascending dose study, with 10 subjects randomized in each group, 8 subjects receiving TNP-2092 and 2 receiving placebo. The drug will be administered once in each group in the fasting state, and tolerability will be evaluated on D4. Subjects were sequentially enrolled into different dose groups in ascending order of dose, and only when the previous lower dose was confirmed to be safe and well tolerated could they be enrolled into the next higher dose group.\n\nThe 400 mg group will complete the single ascending dose study, food effect study and undergo the metabolic transformation evaluation. A total of 18 subjects will be enrolled in the group and randomized into Group A and Group B, with 8 subjects receiving the investigational product and 1 receiving placebo. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days. In terms of the administration sequence, Group A will first take TNP-2092 Capsules or placebo in the fasting state, and then TNP-2092 Capsules or placebo in the fed state; Group B will first take TNP-2092 Capsules or placebo in the fed state, and then TNP-2092 Capsules or placebo in the fasting state. Tolerability evaluation will be conducted on D4 and at the end of the study of food effects on pharmacokinetics (D8).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'genderBased': True, 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Sex: male or female;\n* Age: 18-45 years, inclusive;\n* BMI: 19.0-26.0 kg/m2, inclusive;\n* Female subjects of childbearing potential must agree to practice abstinence or take effective contraceptive measures during the study and at least 70 days (10 weeks) after administration;\n* Male subjects must agree to practice abstinence or use condoms as a contraceptive measure during the study and at least 70 days (10 weeks) after administration;\n* Subjects whose clinical laboratory test results are within the normal range or whose test results are abnormal, but judged by the investigator to be of no clinical insignificance;\n* Those who do not smoke, or have smoked less than 5 cigarettes per day within 3 months before screening; those who do not drink alcohol, or have drunk less than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) within 6 months before screening; those who have not smoked or drunk alcohol within 48 hours before admission to the study site;\n* Those who are fully informed of and understand this study, and have signed the Informed Consent Form;\n* Those who are willing to follow and able to complete all the study procedures.\n\nExclusion Criteria:\n\n* Those with symptoms or medical history of cardiovascular, digestive, respiratory, urinary, neurological, blood, immune, endocrine system diseases or tumor, mental illness, or any situation which, in the opinion of the investigator, may threaten the safety of the subjects or affect the correctness of the study results;\n* Pregnant or lactating women;\n* Those whose blood pressure above 150/90 mmHg or below 85/55 mmHg (supine position);\n* Those with regular use of any prescription/over-the-counter drugs, including vitamins, minerals, nutritional supplements or herbs, within 2 weeks before enrollment and during the study;\n* Those who are HIV positive, syphilis positive, hepatitis B surface antigen positive, hepatitis C antibody positive, and/or with a positive drug urine test result;\n* Those who have a history of alcohol or drug abuse in the past 10 years; Those with an allergic constitution, a history of allergic diseases or a history of drug allergy;\n* Those who have had beverages or foods containing methylxanthine (coffee, tea, coke, chocolate and energy drinks), grapefruit (fruit juice) and alcohol within 48 hours (2 days) before the clinical study;\n* Those who have taken any drug that changes the activity of liver enzymes within 28 days before taking the investigational product or during the study;\n* Those who have donated blood within 3 months before enrollment;\n* Those who have participated in any clinical studies within 3 months before enrollment;\n* Those who are the staff of the study site directly affiliated to this study or are their immediate family members. Immediate family members are defined as spouses, parents, children or siblings, whether related by blood or legally adopted;\n* Those who are employees of TenNor Therapeutics;\n* Other circumstances deemed by the investigator to be unsuitable for the subject to participate in this study.'}, 'identificationModule': {'nctId': 'NCT06178718', 'briefTitle': 'A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules', 'organization': {'class': 'INDUSTRY', 'fullName': 'TenNor Therapeutics Inc.'}, 'officialTitle': 'A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNP-2092 Capsules, and the Food Effect on the Pharmacokinetics of TNP-2092 Capsules After Single-dose Oral Administration in Healthy Subjects', 'orgStudyIdInfo': {'id': 'TNP-2092-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TNP-2092 capsules', 'description': 'In single ascending dose study, participants received single oral dose of TNP-2092 capsules 100 to 1200 mg in fasted state.\n\nIn food effect study, participants received single oral dose of TNP-2092 capsules 400 mg in fasted or fed state in a two-sequence, two-period crossover design.', 'interventionNames': ['Drug: TNP-2092 capsules']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'In single ascending dose study, participants received single oral dose of TNP-2092 placebo capsules in fasted state.\n\nIn food effect study, participants received single oral dose of TNP-2092 placebo capsules in fasted or fed state in a two-sequence, two-period crossover design.', 'interventionNames': ['Drug: TNP-2092 placebo capsules']}], 'interventions': [{'name': 'TNP-2092 capsules', 'type': 'DRUG', 'otherNames': ['Rifaquizinone'], 'description': 'Administered orally, 100 to 1200 mg', 'armGroupLabels': ['TNP-2092 capsules']}, {'name': 'TNP-2092 placebo capsules', 'type': 'DRUG', 'otherNames': ['Placebo'], 'description': 'Administered orally', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Changchun', 'state': 'Jilin', 'country': 'China', 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}], 'overallOfficials': [{'name': 'Yanhua Ding, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The First Hospital of Jilin University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'TenNor Therapeutics (Suzhou) Limited', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'The First Hospital of Jilin University', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}